The World Health Organization (WHO) Director General Tedros Adhanom Ghebreyesus said on Monday that the World Health Organisation has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns.
Tedros said in an official statement that the executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board. He also said that the other arms of the WHO’s so-called solidarity trial, a large international initiative to hold clinical tests of potential treatments for the virus would continue. Dr Mike Ryan added that the decision to suspend trials of hydroxychloroquine had been taken out of an abundance of caution.
Hydroxychloroquine, a drug has been endorsed by the American president Donald Trump and many other leaders as a possible treatment for the disease caused by the novel COVID-19. The US President has said he was taking the drug so as to find and implement whether the drug can be used as a medicine to prevent the infection caused by the COVID-19 pandemic.
Dr Mike Ryan added that the decision to suspend trials of hydroxychloroquine had been taken out of an abundance of caution.